Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients

American Journal of Health-System Pharmacy

Volumn 67, Issue 24, 2010, Pages 2110-2114

  Eaddy, Michael ^a   Seal, Brian ^b   Tangirala, Muralikrishna ^c   Davies, Elizabeth Hackney ^d   O'Day, Ken ^a  

^a XCENDA   (United States)

^b BAYER CORPORATION   (United States)

^c Smith Hanley Consulting Group LLC   (United States)

^d Xcenda   (United States)

Author keywords

Allopurinol; Costs; Critical care; Drug comparisons; Economics; Enzymes; Hospitals; Pediatrics; Rasburicase; Tumor lysis syndrome; Uricosuric agents

Indexed keywords

ALLOPURINOL; RASBURICASE; ANTIGOUT AGENT; ENZYME INHIBITOR; URATE OXIDASE;

ARTICLE; CHILD; CHILDHOOD CANCER; COMORBIDITY; CONTROLLED STUDY; DRUG COST; ELECTROLYTE BALANCE; FEMALE; HOSPITAL ADMISSION; HOSPITAL COST; HUMAN; INTENSIVE CARE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; ADOLESCENT; COMPARATIVE STUDY; ECONOMICS; FACTUAL DATABASE; HEALTH CARE COST; INFANT; METHODOLOGY; RETROSPECTIVE STUDY; TIME;

ADOLESCENT; ALLOPURINOL; CHILD; CHILD, PRESCHOOL; CRITICAL CARE; DATABASES, FACTUAL; ENZYME INHIBITORS; FEMALE; GOUT SUPPRESSANTS; HEALTH CARE COSTS; HUMANS; INFANT; LENGTH OF STAY; MALE; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 79952527390     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100022     Document Type: Article

References (14)

1. Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol. 1995; 9:206-12.
2. Bosley A, Sonet A, Pinkerton CR et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer. Cancer. 2003; 98:1048-54.
3. Pui C, Mahmoud H, Wiley JM et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol. 2001; 19:697-704. (Pubitemid 32119083)
4. Pui C, Jeha S, Irwin D et al. Recombinant urate oxidase in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia. 2001; 15:1505-9. (Pubitemid 32994667)
5. Navolonic PM, Pui C, Larson RA et al. Elitek - rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome. A meeting report. Leukemia. 2003; 17:499-514. (Pubitemid 36395643)
6. Aspen Europe Gmbtt . Zyloric (allopurinol): summary of product characteristics. http://emc.medicines.org.uk/printfriendlydocument.aspx? documentid=4565 (accessed 2009 May 19).
7. Band PR, Silverberg DS, Henderson JF et al. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med. 1970; 283:354-7.
8. Andreoli SP, Clark JH, McGuire WA et al. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr. 1986; 109:292-8. (Pubitemid 16032526)
9. Brogard JM, Coumaros D, Franckhauser J et al. Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase. Rev Eur Etud Clin Biol. 1972; 17:890-5.
10. Patte C, Sakiroglu C, Ansoborlo A et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol. Ann Oncol. 2002; 13:789-95. (Pubitemid 34567388)
11. Bowman WP, Shuster HH, Cook B et al. Improved survival for children with B-cell lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a Pediatric Oncology Group study. J Clin Oncol. 1996; 14:1252-61. (Pubitemid 26105533)
12. Candrilli S, Bell T, Irish W et al. A comparison of inpatient length of stay and costs among patients with hematologic malignancies (excluding Hodgkin disease) associated with and without renal failure. Clin Lymphoma Myeloma. 2008; 8:44-51. (Pubitemid 351449718)
13. Wang L, Shih L, Chang H et al. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies. Acta Haematol. 2006; 115:35-8. (Pubitemid 43130430)
14. Red Book Update. 2010; 30(4):33.